S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

IPA ImmunoPrecise Antibodies Ltd

0.3575

-0.0343 (-8.75%)

11 Mar 2025 - Closed

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more ImmunoPrecise Antibodies Charts.

ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more ImmunoPrecise Antibodies Charts.

ImmunoPrecise Antibodies Ltd News

IPA et RIBOPRO entrent en partenariat pour faire avancer la découverte d'anticorps à base d'ARNm et ouvrir de nouveaux horizons en immunothérapie
Thursday 27 February 2025 (2 weeks ago) • Business Wire

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
Thursday 27 February 2025 (2 weeks ago) • Business Wire

ImmunoPrecise Antibodies annonce un remaniement de son équipe de direction
Tuesday 25 February 2025 (2 weeks ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 25 February 2025 (2 weeks ago) • Edgar (US Regulatory)

ImmunoPrecise Antibodies Announces Key Leadership Changes
Tuesday 25 February 2025 (2 weeks ago) • Business Wire

ImmunoPrecise Antibodies annonce le transfert de l'inscription de ses titres au Nasdaq Capital Market et la prolongation de la période de conformité du prix des offres
Friday 21 February 2025 (3 weeks ago) • Business Wire

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period
Friday 21 February 2025 (3 weeks ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 4 February 2025 (1 month ago) • Edgar (US Regulatory)

ImmunoPrecise Antibodies (IPA) annonce la réalisation d'un placement d'actions sur le marché et la conversion complète de la débenture de Yorkville
Tuesday 28 January 2025 (1 month ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 28 January 2025 (1 month ago) • Edgar (US Regulatory)

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
Tuesday 28 January 2025 (1 month ago) • Business Wire

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Saturday 25 January 2025 (1 month ago) • Edgar (US Regulatory)

More ImmunoPrecise Antibodies Ltd News Articles

National Australia Bank

AUD vs US Dollar

Verizon Communications

Australia And New Zealan...

Newcrest Mining

S&P ASX 300 Metals and M...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions